3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
5
Myeloid
4
Lymphoid
4
Gynecologic
2
Gastrointestinal
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
CNS
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Mesothelioma, Malignant
1
Mesothelioma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Fulvestrant
83
Letrozole
77
Paclitaxel
76
pembrolizumab
72
Specimen Handling
66
Trastuzumab
62
Carboplatin
57
Magnetic Resonance Spectroscopy
51
ribociclib
49
Capecitabine
48
Anastrozole
47
pertuzumab
46
palbociclib
43
exemestane
40
abemaciclib
40
Cyclophosphamide
40
Tamoxifen
39
Biopsy
38
Docetaxel
30
trastuzumab deruxtecan
29
Taxes
28
Radiotherapy
28
Gemcitabine
25
Blood Specimen Collection
25
130-nm albumin-bound paclitaxel
25
olaparib
22
Surveys and Questionnaires
22
Standard of Care
22
sacituzumab govitecan
20
eribulin
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Blood Component Removal
×
Breast
×
90 days
×
Clear all
NCT04981119
2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
200 enrolled